234 related articles for article (PubMed ID: 23510414)
1. Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies.
Warren EH; Deeg HJ
Tissue Antigens; 2013 Apr; 81(4):183-93. PubMed ID: 23510414
[TBL] [Abstract][Full Text] [Related]
2. The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation.
Hadjis AD; McCurdy SR
Front Immunol; 2024; 15():1358668. PubMed ID: 38817602
[TBL] [Abstract][Full Text] [Related]
3. Prevention of graft-versus-host-disease with preserved graft-versus-leukemia-effect by ex vivo and in vivo modulation of CD4(+) T-cells.
Fricke S; Hilger N; Fricke C; Schönfelder U; Behre G; Ruschpler P; Boldt A; Oelkrug C; Sack U; Emmrich F
Cell Mol Life Sci; 2014 Jun; 71(11):2135-48. PubMed ID: 24067988
[TBL] [Abstract][Full Text] [Related]
4. [Evidence of GVHD/GVL in allogeneic hematopoietic stem cell transplantation from sex-mismatched donors].
Nakasone H
Rinsho Ketsueki; 2024; 65(4):265-271. PubMed ID: 38684437
[TBL] [Abstract][Full Text] [Related]
5. Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
Li JM; Giver CR; Lu Y; Hossain MS; Akhtari M; Waller EK
Immunotherapy; 2009 Jul; 1(4):599-621. PubMed ID: 20191089
[TBL] [Abstract][Full Text] [Related]
6. Minor histocompatibility antigens as targets for immunotherapy using allogeneic immune reactions.
Akatsuka Y; Morishima Y; Kuzushima K; Kodera Y; Takahashi T
Cancer Sci; 2007 Aug; 98(8):1139-46. PubMed ID: 17521316
[TBL] [Abstract][Full Text] [Related]
7. The impact of regulatory T cells on the graft-versus-leukemia effect.
Pacini CP; Soares MVD; Lacerda JF
Front Immunol; 2024; 15():1339318. PubMed ID: 38711496
[TBL] [Abstract][Full Text] [Related]
8. Which factors influence the development of GVHD in HLA-matched or mismatched transplants?
Petersdorf EW
Best Pract Res Clin Haematol; 2017 Dec; 30(4):333-335. PubMed ID: 29156205
[TBL] [Abstract][Full Text] [Related]
9. Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia.
Pang Y; Holtzman NG
Best Pract Res Clin Haematol; 2023 Jun; 36(2):101475. PubMed ID: 37353287
[TBL] [Abstract][Full Text] [Related]
10. Risk assessment in haematopoietic stem cell transplantation: histocompatibility.
Petersdorf EW
Best Pract Res Clin Haematol; 2007 Jun; 20(2):155-70. PubMed ID: 17448954
[TBL] [Abstract][Full Text] [Related]
11. The delicate balance of graft versus leukemia and graft versus host disease after allogeneic hematopoietic stem cell transplantation.
Maurer K; Soiffer RJ
Expert Rev Hematol; 2023; 16(12):943-962. PubMed ID: 37906445
[TBL] [Abstract][Full Text] [Related]
12. Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.
Rezvani K; Barrett AJ
Best Pract Res Clin Haematol; 2008 Sep; 21(3):437-53. PubMed ID: 18790448
[TBL] [Abstract][Full Text] [Related]
13. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients.
Chapuis AG; Ragnarsson GB; Nguyen HN; Chaney CN; Pufnock JS; Schmitt TM; Duerkopp N; Roberts IM; Pogosov GL; Ho WY; Ochsenreither S; Wölfl M; Bar M; Radich JP; Yee C; Greenberg PD
Sci Transl Med; 2013 Feb; 5(174):174ra27. PubMed ID: 23447018
[TBL] [Abstract][Full Text] [Related]
14. T cell-mediated graft-versus-leukemia reactions after allogeneic stem cell transplantation.
Schetelig J; Kiani A; Schmitz M; Ehninger G; Bornhäuser M
Cancer Immunol Immunother; 2005 Nov; 54(11):1043-58. PubMed ID: 15887014
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects.
Melenhorst JJ; Leen AM; Bollard CM; Quigley MF; Price DA; Rooney CM; Brenner MK; Barrett AJ; Heslop HE
Blood; 2010 Nov; 116(22):4700-2. PubMed ID: 20709906
[TBL] [Abstract][Full Text] [Related]
16. Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT.
Senjo H; Harada S; Kubota SI; Tanaka Y; Tateno T; Zhang Z; Okada S; Chen X; Kikuchi R; Miyashita N; Onozawa M; Goto H; Endo T; Hasegawa Y; Ohigashi H; Ara T; Hasegawa Y; Murakami M; Teshima T; Hashimoto D
Blood; 2023 Aug; 142(5):477-492. PubMed ID: 37216687
[TBL] [Abstract][Full Text] [Related]
17. The role of immune reconstitution in relapse after allogeneic hematopoietic stem cell transplantation.
Pei XY; Huang XJ
Expert Rev Clin Immunol; 2024 May; 20(5):513-524. PubMed ID: 38599237
[TBL] [Abstract][Full Text] [Related]
18. The Role of Immune Checkpoints after Cellular Therapy.
Schmitz F; Wolf D; Holderried TAW
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32455836
[TBL] [Abstract][Full Text] [Related]
19. Development of a Minor Histocompatibility Antigen Vaccine Regimen in the Canine Model of Hematopoietic Cell Transplantation.
Rosinski SL; Stone B; Graves SS; Fuller DH; De Rosa SC; Spies GA; Mize GJ; Fuller JT; Storb R
Transplantation; 2015 Oct; 99(10):2083-94. PubMed ID: 25965411
[TBL] [Abstract][Full Text] [Related]
20. Metabolic instruction of the graft-versus-leukemia immunity.
Burk AC; Apostolova P
Front Immunol; 2024; 15():1347492. PubMed ID: 38500877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
